Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Recker RR, Marin F, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Farrerons J, Sanz B, Oertel H, Stepan J

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Aug 2009Cited by 84 (Europe PMC)

PMID19338452DOI10.1359/jbmr.090315PepBankPUB-19338452

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialSafety outcome
In postmenopausal women with osteoporosis, fewer patients reported adverse events with teriparatide than strontium ranelate.
In plain wordsIn postmenopausal women with osteoporosis, fewer patients reported adverse events with teriparatide than strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePatients with adverse events
Study
n = 79
Comparator
Strontium ranelate
Outcome group
Adverse events · Whole body
Studied dose
20 microg/d · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Patients with adverse events
41%
teriparatide
Patients with adverse events
70%
strontium ranelate
Source sentences
Summary
There were more patients with adverse events after SrR (70%) than teriparatide (41%) treatment (p = 0.013).
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 microg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis.
Summary · context
Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment.
Report a problemFND-1933845206
02HumanNon-randomized trialActivity measurement
In postmenopausal women with osteoporosis, trabecular mineralization surface did not differ significantly between teriparatide and strontium ranelate.
In plain wordsIn postmenopausal women with osteoporosis, trabecular mineralization surface did not differ significantly between teriparatide and strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTrabecular mineralization surface
Study
n = 51
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/d · subcutaneous · 6 monthsAs given in this study (human).
Measurements
MS/BS
7.73%
teriparatide
MS/BS
5.25%
strontium ranelate
Source sentences
Summary
The mean +/- SD mineralization surfaces as a percent of bone surfaces (MS/BS, %) at the trabecular level were 7.73 +/- 1.48% for teriparatide and 5.25 +/- 1.15% for SrR (p = 0.219) and at the endocortical level were 17.22 +/- 3.06% and 9.70 +/- 2.07%, respectively (p = 0.052).
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 microg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis.
Summary · context
Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment.
Report a problemFND-1933845201
03HumanNon-randomized trialActivity measurement
In postmenopausal women with osteoporosis, endocortical mineralization surface did not differ significantly between teriparatide and strontium ranelate.
In plain wordsIn postmenopausal women with osteoporosis, endocortical mineralization surface did not differ significantly between teriparatide and strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeEndocortical mineralization surface
Study
n = 51
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/d · subcutaneous · 6 monthsAs given in this study (human).
Measurements
MS/BS
17.22%
teriparatide
MS/BS
9.7%
strontium ranelate
Source sentences
Summary
The mean +/- SD mineralization surfaces as a percent of bone surfaces (MS/BS, %) at the trabecular level were 7.73 +/- 1.48% for teriparatide and 5.25 +/- 1.15% for SrR (p = 0.219) and at the endocortical level were 17.22 +/- 3.06% and 9.70 +/- 2.07%, respectively (p = 0.052).
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 microg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis.
Summary · context
Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment.
Report a problemFND-1933845202
04HumanNon-randomized trialActivity measurement
In postmenopausal women with osteoporosis, cortical porosity was greater with teriparatide than strontium ranelate.
In plain wordsIn postmenopausal women with osteoporosis, cortical bone porosity was greater with teriparatide than strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical porosity
Study
n = 51
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/d · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Cortical porosity
5.4%
teriparatide
Cortical porosity
4.14%
strontium ranelate
Source sentences
Summary
Cortical porosity was 5.40 +/- 0.41% in the teriparatide and 4.14 +/- 0.40% in the SrR group (p = 0.037).
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 microg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis.
Summary · context
Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment.
Report a problemFND-1933845203
05HumanNon-randomized trialActivity measurement
In postmenopausal women with osteoporosis, teriparatide increased PINP from baseline after one month.
In plain wordsIn postmenopausal women with osteoporosis, teriparatide increased a bone formation marker from baseline after one month.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP
Study
n = 39
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/d · subcutaneous · 1 monthAs given in this study (human).
Measurements
PINP change
57%
from baseline after 1 month
Source sentences
Summary
Teriparatide induced significant increases from baseline in bone formation and resorption markers, reaching statistical significance for amino-terminal propeptide of type I collagen (PINP) after 1 mo (+57%, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 microg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis.
Summary · context
Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment.
Report a problemFND-1933845204
06HumanNon-randomized trialActivity measurement
In postmenopausal women with osteoporosis, teriparatide increased bone resorption markers from baseline.
In plain wordsIn postmenopausal women with osteoporosis, bone breakdown markers increased from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone resorption markers
Study
n = 39
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/d · subcutaneousAs given in this study (human).
Source sentences
Summary
Teriparatide induced significant increases from baseline in bone formation and resorption markers, reaching statistical significance for amino-terminal propeptide of type I collagen (PINP) after 1 mo (+57%, p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 microg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis.
Summary · context
Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment.
Report a problemFND-1933845205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.